Investorideas.com - Viridian Cannabis Deal Tracker Chart Of The Week
Get the latest Cannabis and Hemp stock news from www.investorideas.com
Monday 21 September 2020
Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 470 (OTCQB: $CTABF) (OTC: $CSUI), (OTCQX: $AVCNF), (TSXV: $PCLO.V) (OTCQX: $PCLOF)
Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 470 (OTCQB: $CTABF) (OTC: $CSUI), (OTCQX: $AVCNF), (TSXV: $PCLO.V) (OTCQX: $PCLOF)
Today’s
podcast sponsored by Cannabis Suisse Corp. (OTC: $CSUI), a fully licensed
cannabis cultivation and distribution company in Switzerland
Delta, Kelowna, BC, September 21, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
https://www.investorideas.com/Audio/Podcasts/2020/092120-StocksToWatch.mp3
Read this in full
at https://www.investorideas.com/news/2020/cannabis-potcasts/09211CTABF-CSUI-AVCNF-PCLO-PCLOF.asp
Hear the investor ideas potcast on
Spotify
Hear Investor ideas cannabis potcast on iTunes
Today’s podcast overview/transcript:
Good
afternoon and welcome to another episode of Investorideas.com
"Potcast" featuring cannabis news, stocks to watch as well as
insights from thought leaders and experts.
Today’s podcast is
sponsored by Cannabis Suisse Corp. (OTC: CSUI ), a fully licensed cannabis
cultivation and distribution company in Switzerland, for recreational tobacco
products and medical CBD oils. The Company's facilities for producing cannabis
are based in Dietikon, Switzerland, and contain the art surveillance equipment
to enable an around the clock webcast. Cannabis Suisse grows high quality,
organic cannabis with sustainable, all-natural principles. The Company's
products are laboratory tested to ensure the end users have access to a
standardized, safe and consistent product. Cannabis Suisse proprietary
trademarked MoldStandard is a quantitative microbiology method for analyzing yeast
and mold counts in harvested cannabis plants. Cannabis Suisse proprietary
trademarked CannaMec is a method for quantifying and removing residual solvents
during packaging and storage of CBD products. Cannabis Suisse Corp. currently
sells via a distribution network of Swiss retailers and online shops, under the
retail brand Alpine Cannabis.
In
today’s podcast we look at a few public company announcements.
Canntab
Therapeutics Limited (CSE: PILL) (OTCQB: CTABF), the leading innovator in
cannabinoid and terpene blends in hard pill form for therapeutic applications, announced that, pursuant to a filing made in
March 2017, the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent
No. 10,772,837 to Canntab, titled "Modified Release Multi-Layer Tablet
Cannabinoid Formulations. The term of the patent expires on March 15, 2038.
Larry
Latowsky, CEO of Canntab said "this is a major milestone that confirms our
proprietary formulations are unique and differentiated from other product
offerings in the global marketplace which will support a faster revenue stream
as we begin production and distribution in the immediate future. This is the
first patent that was issued to date out of the 13 that we have applied for, and
will be leveraged to solidify Canntab's position as the leader in solid dose
(hard pill) formulations of medicinal cannabinoids.
The
patent granted is for Canntab's bi-layer or multi-layer tablets consisting of
both Instant Release ("IR") and Extended Release ('XR")
formulations with THC, CBD and a variety of Terpenes and other Cannabinoids
found in full spectrum Cannabis and Hemp oil resin.
Canntab
believes that its hard pill formulations are superior to all other CBD and THC
delivery systems since they are true pharmaceutical grade delivery systems
which provide for superior ingredient stability, enhanced bioavailability, and
provide customizable and precise dosing. Canntab believes and intends to prove
greater bioavailability through a blood level study at a 3rd party Clinical
Research Organization (CRO). In addition, whether it is for medical,
recreational or nutraceutical purposes, Canntab is able to provide extended
release formulations making it the clear delivery choice for doctors, patients
or the average consumer.
"Canntab
expects this and future patents to be very valuable in the development of our
strategic partnerships and alliances and in our efforts to secure worldwide
distribution of our proprietary products. As the medical community continues to
recognize Cannabinoid alternatives to traditional therapies, we will continue
to develop innovative approaches to support many clinical applications" continued
Latowsky.
In
addition, Canntab is conducting research to confirm its belief that its
combined CBD and THC tablet can be effective to treat nicotine, alcohol,
cannabis, opioid and other forms of addiction. Canntab will be using a
derivative of these formulations for its clinical trial with Dr. Donald Garbuz
from the University of British Columbia and as previously released in December
2018. This study aims to demonstrate the potential for the reduction or
elimination of the use of opiates in patients during post-operative pain
management.
This
issued patent covers Canntab's modified release pharmaceutical compositions and
more specifically compositions comprising cannabinoids and a process for
preparation thereof as well as methods for administering the compositions to
human users. The compositions may contain a combination of ingredients in
proportions calculated to achieve therapeutic effect.
Canntab
has filed applications for 13 patents in Canada and the United States that
cover a range of processes and formulations that it uses to create its
precision oral-delivery hard tablets, the future of medical cannabis. These
patents include Canntab's proprietary nano-emulsification technology,
granulation process, methods of manufacturing and covers its full line of
precision oral-delivery hard tablets including instant (immediate) release
tablets, extended release tablets, oral dissolvable tablets. Canntab has also
filed a patent for an exclusive formulation of THC and CBD for the treatment of
opioid addiction treatment therapy.
Cannabis
Suisse Corp. (OTC:CSUI), a fully licensed Swiss cannabis
cultivation and distribution company for recreational tobacco products and
medical CBD oils, announced the company’s online expansion plans
including the upcoming launch of a new brand on Amazon.
Сannabis Suisse Corp. is developing
its own line of products including hemp oil, hemp protein, hemp gummies and
hemp hearts with all the appropriate certificates and licenses for sale on
Amazon.
This news follows a recent
announcement for online distribution of its cannabis and CBD products with
uWeed from their retail outlets and online store (www.uweed.ch).
The expansion into online sales of
hemp gives the company headquartered in Switzerland, wider access and inroads
into the US markets and the legal environment for CBD products evolves.
Mr. Alain Parrik, COO & Director
said, " Amazon, is an important distribution outlet for us as we ramp up
for expansion across multiple online retail platforms. Introducing a new line
of hemp products paves the wave for additional products in the future."
Cannabis Suisse Corp. will be in
compliance with Amazon rules and respects their position that CBD is currently
banned on Amazon but hemp products are not.
The Company, as a registered
manufacturer of both products, will continue to use flowers with the highest
concentration of CBD. For the new Amazon product line, oil will be squeezed
from the seeds allowing Cannabis Suisse to use the whole plant in its
production and benefit from it.
Avicanna Inc. (TSX: AVCN) (OTCQX: AVCNF), a biopharmaceutical company
focused on the development, manufacturing and commercialization of
plant-derived cannabinoid-based products, announced that its advanced RHO Phyto Rapid
Act Sprays are now officially available nationwide in Canada on the Medical
Cannabis by Shoppers portal, as well as through the Medical Cannabis Real-World
Evidence Study at the University Health Network.
Avicanna's
RHO Phyto product line is now commercially available after years of research
and development through collaborations with world class academic and clinical
organizations. The development of RHO Phyto products has focused on the key
properties in drug development that health care providers seek when
recommending a medical product to their patients such as formulation stability
for consistent dosing, enhanced absorption and a range of onset times.
The
Rapid Act Spray is a sublingual spray and is among the second set of Avicanna's
RHO Phyto products available for purchase through Shoppers. The sublingual
sprays bypass first-pass metabolism and are quickly absorbed in the mucosal lining
under the tongue. The RHO Phyto Rapid Act Spray provides an alternative
delivery form to the RHO Phyto Micro Drops (also available for sale through
Shoppers) which are absorbed through the oral route. The RHO Phyto Rapid Act
Sprays have been formulated with specific ingredients that enhance absorption
and the onset time of cannabinoids across the mucous membrane beneath the
tongue. The lemon-mint flavoured sprays will be available in 10:20 CBD and 2:40
(w/w) THC to CBD ratios.
Dr.
Justin Grant, Avicanna's Executive Vice President of Scientific Affairs,
commented, "The RHO Phyto Rapid Act Sprays are designed for faster onset
and can be used in acute conditions where patients seek faster relief. The
sublingual sprays can also be used to supplement slower and longer acting
products, such as the RHO Phyto Micro Drop, when occasional higher doses may be
required. Sublingual administration provides an alternative to the potentially
harmful effects of consuming inhalation products."
In
August 2020, Avicanna launched its blood orange flavoured RHO Phyto Micro Drop
2:50 CBD and Micro Drop 5:20 CBD. In the coming months, Avicanna will be
launching its much-anticipated RHO Phyto Deep Tissue Gel, Daily Cream and
Simple Dose Capsules. To ensure batch-to-batch consistency and high-quality
products, these formulations are manufactured at MediPharm Labs Inc, a Good
Manufacturing Practices ("GMP")
certified facility. In addition to strict GMP manufacturing, all RHO Phyto
products undergo GMP-level analytical testing by Sigma Analytical Services Inc.
and use blockchain technology developed by TruTrace Technologies Inc. to
manage, track and trace each step of the supply chain.
Detailed
guidelines outlining dosing and titration for Health Care Practitioners ("HCPs") and patients is available
on the RHO Phyto website at www.rhophyto.com. In addition, the Avicanna
Academy includes additional product information for patients, frequently asked
questions, and a recording of Avicanna's 3rd annual symposium which was hosted
virtually in partnership with Shoppers on July 21, 2020. For more information
visit https://www.avicanna.com/the-avicanna-academy/.
The
Company has also re-branded and re-launched its subsidiary, My Cannabis Clinic
(formerly known as My Cannabis), which specializes in assisting patients to
gain access to medical cannabis and cannabinoid-based products for medical use.
My Cannabis Clinic is devoted to providing HCPs and patients with the support
and education needed for medical cannabis use. My Cannabis Clinic believes in
providing quality care to patients and providing education on the
considerations and potential benefits that cannabis has to offer for medical
use. Information about My Cannabis Clinic can be found at https://mycannabisclinic.org/.
PharmaCielo
Ltd.
(TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of
Colombia's premier cultivator and producer of medicinal-grade cannabis
extracts, PharmaCielo Colombia Holdings S.A.S., announced today that it has begun sales and
distribution of an expanded range of medicinal-grade cannabis extracts
cultivated and produced at its Rionegro facilities.
PharmaCielo has been enabled to
address customer product inquiries based on technical experience to date
combined with increased laboratory and processing capabilities and allowing it
to begin commercial production of a significantly expanded range of extract
products that began with CBD Isolate and
now includes Broad Spectrum Oil, CBD
Broad Spectrum Distillate, Water Soluble
CBD, CBD Tincture, CBD Distillate
Tincture, Full Spectrum Oil Tincture, THC:CBD Formulations and THC Distillate.
"The ability to offer a wide
range of bulk products which vary in cannabinoids combination, potency and
terpenes content is highly sought-after in the medicinal and wellness sector,
as some specific products deliver specific benefits, while others can deliver a
full suite of cannabinoid benefits, known as the entourage effect," said
David Attard, CEO of PharmaCielo Ltd.
"With our different formulations we are also able to provide
customers with the flexibility to formulate their final product according to
the individual health and drug delivery system needs."
Each of PharmaCielo's extracts are
derived from unique and proprietary cultivars developed by the Company's
horticultural research experts, optimized for year-round Colombian open-field
cultivation, with each extract profile reflecting the unique nature of the
cultivar. By example, Broad Spectrum Oil
is carefully purified to yield a beautiful amber coloured cannabinoid-rich
extract that features multiple cannabinoids, including Cannabidiol (CBD),
Cannabidiolic Acid (CBDA), Cannabigerol (CBG), Cannabichromene (CBC),
Cannabidivarin (CBDV) and complemented by a range of naturally occurring
terpenes including Pinene, Limonene, Linalool, and Myrceneas as part of its
attributes.
The expansion of PharmaCielo's
product portfolio comes on the heels of a multi-year investment in its
processing and extraction capabilities. The Company has begun processing part
of its formulations at the expanded facility and is in the position to meet
customer demand for commercial volumes at consistent high-quality, purity and
potency levels required by healthcare standards.
"As we developed the new
product range, based on customer and prospect demand, our team placed a greater
emphasis on ensuring we added Water Soluble CBD extract to the mix. The
development of this product in particular, will enable PharmaCielo to explore
integration opportunities with major players in the health-oriented beverage
and topical products segments of the market, which have expressed interest in
CBD additives," added Attard.
The Company has begun to accept
orders for initial shipments of the new products in the balance of 2020, with
continuing production capacity and shipments volumes increasing into 2021. The
portfolio of extract products available in commercial volumes appropriate to
the global market is expanding on a continuing basis with future additional
product introductions expected.
Individual product profiles and pricing are available through sales@pharmacielo.com.
Once again, today’s podcast is sponsored by Cannabis Suisse Corp. (OTC: CSUI ), a fully licensed cannabis cultivation and distribution company in Switzerland, for recreational tobacco products and medical CBD oils. The Company's products are laboratory tested to ensure the end users have access to a standardized, safe and consistent product. Cannabis Suisse Corp. currently sells via a distribution network of Swiss retailers and online shops, under the retail brand Alpine Cannabis.
Investor ideas reminds all
listeners to read our disclaimers and disclosures on the Investorideas.com
website and that this podcast is not an endorsement to buy products or services
or securities. Investors are reminded all investment involves risk and possible
loss of investment.
Learn more about
our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
Hear Investor ideas cannabis potcast on iTunes
Hear the investor ideas potcast on Spotify
To hear more
Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
Investorideas.com
podcasts are also available on iTunes,
Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified
word mark Trademark on the blockchain through Cognate, Inc. CM
Certification-Registration Number: 10468217708
About Investorideas.com - News that
Inspires Big Investing Ideas
Investorideas.com
is a recognized news source publishing third party news, research and original
financial content. Learn about investing in stocks and sector trends with our
news alerts, articles, podcasts
and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech,
water, renewable energy and more. Investor Idea’s original branded content
includes the following podcasts and columns : Crypto
Corner , Play by Play sports and stock news column, Investor
Ideas Potcasts Cannabis News and Stocks on the Move podcast and
column, Cleantech and Climate Change , Exploring Mining the AI Eye .
Disclaimer/Disclosure: Investorideas.com is a
digital publisher of third party sourced news, articles and equity research as
well as creates original content, including video, interviews and articles.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Our site does not make recommendations for purchases
or sale of stocks, services or products. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities.
All investing involves risk and possible losses. This site is currently
compensated for news publication and distribution, social media and marketing,
content creation and more. Disclosure is posted for each compensated news
release, content published /created if required but otherwise the news was not
compensated for and was published for the sole interest of our readers and
followers. Contact management and IR of each company directly regarding
specific questions. Disclosure: Cannabis
Suisse Corp. (OTC: CSUI ),is a paid featured company on
Investorideas.com More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our
other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each country.
Please read Investorideas.com privacy policy:
https://www.investorideas.com/About/Private_Policy.asp.
Follow us on Twitter https://twitter.com/Investorideas
Follow
us on Facebook https://www.facebook.com/Investorideas
Follow
us on YouTube https://www.youtube.com/c/Investorideas
Download
our Mobile App for
iPhone and Android
Join
our Investor Club https://www.investorideas.com/membership/
Contact Investorideas.com
800
665 0411
Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory
Cannabis Stock News: Cannabis Suisse Corp. (OTC: $CSUI) Expansion Plans for Online Sales, Adding to CBD product lines with New Hemp Brands @SuisseCorp
Cannabis Stock News: Cannabis Suisse Corp. (OTC: $CSUI) Expansion Plans for
Online Sales, Adding to CBD product lines with New Hemp Brands @SuisseCorp
Company plans to expand online sales with retail
giant Amazon ( $AMZN)
DIETIKON, SWITZERLAND - Cannabis Suisse Corp. (OTC: CSUI), a fully licensed Swiss cannabis cultivation and distribution company for recreational tobacco products and medical CBD oils, announces online expansion plans including the upcoming launch of a new brand on Amazon.
Read this news featuring CSUI in full at https://www.investorideas.com/CO/CSUI/news/2020/09211Expansion-Plans.asp
Сannabis
Suisse Corp. is developing its own line of products including hemp oil, hemp
protein, hemp gummies and hemp hearts with all the appropriate certificates and
licenses, for sale on Amazon.
This news
follows a recent announcement for
online distribution of its cannabis and CBD products with uWeed from their retail
outlets and online store (www.uweed.ch).
The expansion into online sales
of hemp gives the company, which is headquartered in Switzerland, wider access and
inroads into US markets as the legal environment for CBD products evolves.
Mr. Alain Parrik, COO & Director said, “Amazon
is an important distribution outlet for us as we ramp up for expansion across
multiple online retail platforms. Introducing a new line of hemp products paves
the wave for additional products in the future.”
Cannabis Suisse Corp. will be in compliance with
Amazon rules and respects their position that CBD is currently banned on Amazon
but hemp products are not.
The
Company, as a registered manufacturer of both products will continue to use
flowers with the highest concentration of CBD. For the new Amazon product line,
oil will be squeezed from the seeds allowing Cannabis Suisse to use the whole
plant in its production and benefit from it.
Source: Brightfield Group Quarterly CBD Consumer
Survey, Q2, 2020, Sample size = 5,000
Price Compression
ABOUT CANNABIS SUISSE CORP.
Cannabis Suisse Corp. is a fully licensed cannabis
cultivation and distribution company in
Switzerland, for recreational tobacco products and medical CBD oils. The
Company’s facilities for producing cannabis are based in Dietikon, Switzerland,
and contain the art surveillance equipment to enable an around the clock
webcast. Cannabis Suisse grows high quality, organic cannabis with sustainable,
all-natural principles. The Company’s products are laboratory tested to ensure
the end users have access to a standardized, safe and consistent product.
Cannabis Suisse proprietary trademarked MoldStandard is a quantitative
microbiology method for analyzing yeast and mold counts in harvested cannabis
plants. Cannabis Suisse proprietary trademarked CannaMec is a method for
quantifying and removing residual solvents during packaging and storage of CBD
products. Cannabis Suisse Corp. currently sells via a distribution network of
Swiss retailers and online shops, under the retail brand Alpine Cannabis.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and
information, as defined within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject
to the Safe Harbor created by those sections.
This material contains statements about expected future events and/or
financial results that are forward-looking in nature and subject to risks and
uncertainties. Such forward-looking statements by definition involve risks,
uncertainties and other factors, which may cause the actual results,
performance or achievements of Cannabis Suisse Corp. to be materially different
from the statements made herein.
CONTACT:
Alain Parrik
Cannabis Suisse Corp.
+41445865314
alain.parrik@cannabissuisse.biz
SOURCE: Cannabis Suisse Corp
Cannabis
Suisse (OTC: CSUI) is a featured Cannabis stock on Investorideas.com
Disclaimer/Disclosure: Investorideas.com is a digital publisher
of third party sourced news, articles and equity research as well as creates
original content, including video, interviews and articles. Original content
created by investorideas is protected by copyright laws other than syndication
rights. Our site does not make recommendations for purchases or sale of stocks,
services or products. Nothing on our sites should be construed as an offer or
solicitation to buy or sell products or securities. All investing involves risk
and possible losses. This site is currently compensated for news publication
and distribution, social media and marketing, content creation and more.
Disclosure is posted for each compensated news release, content published
/created if required but otherwise the news was not compensated for and was
published for the sole interest of our readers and followers. Contact
management and IR of each company directly regarding specific questions.
Disclosure : Cannabis Suisse Corp. (OTC: CSUI) is a paid monthly
cannabis company on Investorideas.com ( five thousand per month) More
disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our
other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each country.
Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of cannabis except where
permissible by law. Our site does not possess, distribute, or sell cannabis
products.
Get
more Cannabis Stock Investor Ideas - news,
articles, podcasts and stock
directories
Buy a cannabis guest post on Investorideas.com
Friday 18 September 2020
#Cannabis #Stock news - Cannabis Suisse (OTC: $CSUI) Reports New Service "Your Cannabis Grow" to the European Market; @SuisseCorp
#Cannabis #Stock news - Cannabis Suisse (OTC: $CSUI) Reports New Service
"Your Cannabis Grow" to the European Market; @SuisseCorp
DIETIKON, SWITZERLAND, September 18, 2020 - ( Investorideas.com newswire) – cannabis stock news - Cannabis Suisse (OTC: CSUI),recently reported a new service to the European market, Your Cannabis Grow, an innovative service which allows customers from Europe to grow their own cannabis seedling in one of Cannabis Suisse's indoor farms located in Switzerland.
Read this news featuring CSUI in full at https://www.investorideas.com/CO/CSUI/news/2020/09181Your-Cannabis-Grow-European-Market.asp
This is an ethical, transparent and sustainable way to
source the product containing essential CBD and EU sanctioned levels of THC -
individually cultivated straight from the farm. Cannabis Suisse experts will
monitor the entire cultivation process daily.
Customers can choose from an array of different
cannabis strains. All the customers will be provided with a live video where
they can watch the growth of the plants from the first seeding till the final
harvest. The entire growth cycle of a cannabis plant is approximately 8-10
weeks, drying time is between 7-13 days. After being harvested, the THC level
within the weed needs to be adjusted to meet the legal criteria of the country
where the customer resides, then customers can have their weed shipped directly
to their home. Harvest result is usually between 20 and 35 gr. per plant. On
site, the plants are taken care of by Cannabis Suisse's master growers that are
also involved in manufacturing of all the other products.
The price of 120 CHF includes all these services.
Cannabis Suisse clients get a clone, a nameplate, a weekly photo of the plant,
a certificate of the plant owner, photos of their drying plate, and as a result
flowerheads shipped from the farm in anonymous packages.
The product can be ordered from the special website of
the Company and from selected resellers. Cannabis Suisse Corp. also plans to
sell it via a network of kiosks where customers can buy a plastic card already
containing login and password data for the website. The intention is to do it
especially in those type of kiosks that identify themselves as tobacco shops.
Buying a card, customers are always sure that there is free space available at
the farm.
In connection with the expansion of its services,
Cannabis Suisse Corp. announces many special offers for its customers. There is
giving out of 10 plants only for the subscribing to the Company's newsletters.
As well ordering three plants at once, a buyer will receive the fourth one as a
gift. Cannabis Suisse Corp. also offers open days. On selected days, the
growers will be happy to welcome their customers personally at the facility.
Your Cannabis Grow is a hassle-free way to grow your
own weed, there are many benefits and saving money is not the only one. Growing
own cannabis plant has never been easier if the plant is in the hands of
Cannabis Suisse's master growers. Cannabis Suisse has a top tier indoor farm
that has no contaminants, customers' plants will be cared the same way as the
rest of the products and receive the optimal conditions to grow and flourish.
Growing own hemp is tricky even if it is grown only during the summer when
there is not any need for special equipment.
Your Cannabis Grow is a service for everyone, but
savvy customers that are well-versed in the different kinds of strains and
already know what they prefer for regular consumption are going to see this
service as an essential one. For someone who is experimenting, looking for new
flavors or maybe new to cannabis consumption, Your Cannabis Grow might not be a
commitment that is worth taking just yet. However, once a client has found that
special strain, Your Cannabis Grow is a certain way to make sure that the
strain is always in stock and even cheaper than ready-made products.
At the moment, a customer can choose from 6 different
cannabis strains that give different aroma, taste and experiences. They are V1,
Harlequin, White Alpine, Limoncello, Orange Alpine, Strawberry. This a great
selection at launch and is going to be expanded and improved in the future.
Growing medical marijuana is legal in some European
countries, but in Switzerland it is allowed to grow and sell cannabis for
recreational or commercial use. It makes Switzerland unique and gives some
interesting benefits for companies such as Cannabis Suisse Corp. Cannabis
Suisse is using this opportunity to create a new market while also benefiting
customers with a chance to own a legal cannabis farm plant that definitely has
more benefits than having one in a back yard.
Cannabis Suisse Corp. is a forward-looking company and
understands that consistent quality, trust and community creates a strong
brand. The Company creates innovate products that people need and want to buy.
Your Cannabis Grow is a service that is hopefully going to create a community
that will trust in Cannabis Suisse future products and believe them to be worth
sharing and supporting.
The release of Your Cannabis Grow is a new step for
Cannabis Suisse Corp., while being extremely beneficial to customers. The
service requires a time investment, but the outcome and saving are definitely
worth the waiting. The service will evolve in the future and could even become
an industry standard.
ABOUT CANNABIS SUISSE CORP.
Cannabis Suisse Corp. is a fully licensed cannabis
cultivation and distribution company in Switzerland, for recreational tobacco
products and medical CBD oils. The Company's facilities for producing cannabis
are based in Dietikon, Switzerland, and contain the art surveillance equipment
to enable an around the clock webcast. Cannabis Suisse grows high quality,
organic cannabis with sustainable, all-natural principles. The Company's
products are laboratory tested to ensure the end users have access to a
standardized, safe and consistent product. Cannabis Suisse proprietary
trademarked MoldStandard is a quantitative microbiology method for analyzing
yeast and mold counts in harvested cannabis plants. Cannabis Suisse proprietary
trademarked CannaMec is a method for quantifying and removing residual solvents
during packaging and storage of CBD products. Cannabis Suisse Corp. currently
sells via a distribution network of Swiss retailers and online shops, under the
retail brand Alpine Cannabis.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking
statements and information, as defined within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934,
and is subject to the Safe Harbor created by those sections. This material
contains statements about expected future events and/or financial results that
are forward-looking in nature and subject to risks and uncertainties. Such
forward-looking statements by definition involve risks, uncertainties and other
factors, which may cause the actual results, performance or achievements of
Cannabis Suisse Corp. to be materially different from the statements made
herein.
CONTACT:
Alain Parrik
Cannabis Suisse Corp.
+41445865314
alain.parrik@cannabissuisse.biz
SOURCE: Cannabis Suisse Corp
Cannabis Suisse (OTC: CSUI) is a featured Cannabis
stock on Investorideas.com
Disclaimer/Disclosure: Investorideas.com
is a digital publisher of third party sourced news, articles and equity
research as well as creates original content, including video, interviews and
articles. Original content created by investorideas is protected by copyright
laws other than syndication rights. Our site does not make recommendations for
purchases or sale of stocks, services or products. Nothing on our sites should
be construed as an offer or solicitation to buy or sell products or securities.
All investing involves risk and possible losses. This site is currently
compensated for news publication and distribution, social media and marketing,
content creation and more. Disclosure is posted for each compensated news
release, content published /created if required but otherwise the news was not
compensated for and was published for the sole interest of our readers and
followers. Contact management and IR of each company directly regarding
specific questions.
Disclosure : Cannabis Suisse Corp. (OTC:
CSUI) is a paid monthly cannabis company on Investorideas.com ( five thousand
per month) More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn
more about publishing your news release and our other news services on the
Investorideas.com newswire https://www.investorideas.com/News-Upload/ and
tickertagstocknews.com
Global investors must adhere to
regulations of each country. Please read Investorideas.com privacy
policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use
of cannabis except where permissible by law. Our site does not possess,
distribute, or sell cannabis products.
Get more Cannabis
Stock Investor Ideas - news, articles, podcasts and stock directories
Buy a cannabis guest post on Investorideas.com
Subscribe to:
Posts (Atom)
-
Investorideas.com - Cannabis Stock News: TransCanna (CSE: TCAN) Product Ranks in Leafly's Top Cannabis Strains List
-
Investorideas.com - CBD Stock News: InnoCan Pharma (CSE: INNO) Announces the Successful Completion of an Independent Clinical Study Demonstr...
-
New #Cannabis Stocks Added to Investor Ideas; (TSX: $FAF.V) (CSE: $STIL.C) (CSE: $ORCD.C) (CSE: $VREO.C) (CSE: $PUMP.C) (OTC: $NUGL) ...